Macrophage migration inhibitory factor: a potential biomarker for chronic low back pain in patients with Modic changes
Background Low back pain (LBP) is a leading cause of disability worldwide, but the aetiology remains poorly understood. Finding relevant biomarkers may lead to better understanding of disease mechanisms. Patients with vertebral endplate bone marrow lesions visualised on MRI as Modic changes (MCs) ha...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2021-08-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/7/2/e001726.full |
| _version_ | 1818643568402628608 |
|---|---|
| author | Are Hugo Pripp Kjersti Storheim Lars Christian Haugli Bråten Monica Wigemyr Maria Dehli Vigeland John Anker Zwart Linda Margareth Pedersen Elisabeth Gjefsen Kristina Gervin Guro Goll Hans Christian D Aass Elina Schistad Kaja Kristine Selmer |
| author_facet | Are Hugo Pripp Kjersti Storheim Lars Christian Haugli Bråten Monica Wigemyr Maria Dehli Vigeland John Anker Zwart Linda Margareth Pedersen Elisabeth Gjefsen Kristina Gervin Guro Goll Hans Christian D Aass Elina Schistad Kaja Kristine Selmer |
| author_sort | Are Hugo Pripp |
| collection | DOAJ |
| description | Background Low back pain (LBP) is a leading cause of disability worldwide, but the aetiology remains poorly understood. Finding relevant biomarkers may lead to better understanding of disease mechanisms. Patients with vertebral endplate bone marrow lesions visualised on MRI as Modic changes (MCs) have been proposed as a distinct LBP phenotype, and inflammatory mediators may be involved in the development of MCs.Objectives To identify possible serum biomarkers for LBP in patients with MCs.Methods In this case control study serum levels of 40 cytokines were compared between patients with LBP and MC type 1 (n=46) or type 2 (n=37) and healthy controls (n=50).Results Analyses identified significantly higher levels of six out of 40 cytokines in the MC type 1 group (MC1), and five in the MC type 2 group (MC2) compared with healthy controls. Six cytokines were moderately correlated with pain. Principal component analyses revealed clustering and separation of patients with LBP and controls, capturing 40.8% of the total variance, with 10 cytokines contributing to the separation. Macrophage migration inhibitory factor (MIF) alone accounted for 92% of the total contribution. Further, receiver operating characteristics analysis revealed that MIF showed an acceptable ability to distinguish between patients and controls (area under the curve=0.79).Conclusions These results suggest that cytokines may play a role in LBP with MCs. The clinical significance of the findings is unknown. MIF strongly contributed to clustering of patients with LBP with MCs and controls, and might be a biomarker for MCs. Ultimately, these results may guide future research on novel treatments for this patient group. |
| first_indexed | 2024-12-17T00:01:01Z |
| format | Article |
| id | doaj.art-bb5274b114604cb0904c3ef4b5c80c50 |
| institution | Directory Open Access Journal |
| issn | 2056-5933 |
| language | English |
| last_indexed | 2024-12-17T00:01:01Z |
| publishDate | 2021-08-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | RMD Open |
| spelling | doaj.art-bb5274b114604cb0904c3ef4b5c80c502022-12-21T22:11:05ZengBMJ Publishing GroupRMD Open2056-59332021-08-017210.1136/rmdopen-2021-001726Macrophage migration inhibitory factor: a potential biomarker for chronic low back pain in patients with Modic changesAre Hugo Pripp0Kjersti Storheim1Lars Christian Haugli Bråten2Monica Wigemyr3Maria Dehli Vigeland4John Anker Zwart5Linda Margareth Pedersen6Elisabeth Gjefsen7Kristina Gervin8Guro Goll9Hans Christian D Aass10Elina Schistad11Kaja Kristine Selmer12Oslo Centre of Biostatistics and Epidemiology Research Support Services, Oslo University Hospital Ullevaal, Oslo, NorwayCommunication and Research Unit for Musculoskeletal Disorders, Oslo universitetssykehus Ulleval, Oslo, NorwayDepartment of Research and Innovation, Oslo University Hospital, Oslo, NorwayDepartment of Research and Innovation, Oslo University Hospital, Oslo, NorwayFaculty of Medicine, University of Oslo, Oslo, NorwayFaculty of Medicine, University of Oslo, Oslo, NorwayDepartment of Research and Innovation, Oslo University Hospital, Oslo, NorwayCommunication and Research Unit for Musculoskeletal Disorders, Oslo universitetssykehus Ulleval, Oslo, NorwayDepartment of Research and Innovation, Oslo University Hospital, Oslo, NorwayDepartment of Rheumatology, Diakonhjemmet Hospital, Oslo, NorwayDepartment of Medical Biochemistry, Oslo University Hospital, Oslo, NorwayDepartment of Physical Medicine and Rehabilitation, Oslo University Hospital, Oslo, NorwayDepartment of Research and Innovation, Oslo University Hospital, Oslo, NorwayBackground Low back pain (LBP) is a leading cause of disability worldwide, but the aetiology remains poorly understood. Finding relevant biomarkers may lead to better understanding of disease mechanisms. Patients with vertebral endplate bone marrow lesions visualised on MRI as Modic changes (MCs) have been proposed as a distinct LBP phenotype, and inflammatory mediators may be involved in the development of MCs.Objectives To identify possible serum biomarkers for LBP in patients with MCs.Methods In this case control study serum levels of 40 cytokines were compared between patients with LBP and MC type 1 (n=46) or type 2 (n=37) and healthy controls (n=50).Results Analyses identified significantly higher levels of six out of 40 cytokines in the MC type 1 group (MC1), and five in the MC type 2 group (MC2) compared with healthy controls. Six cytokines were moderately correlated with pain. Principal component analyses revealed clustering and separation of patients with LBP and controls, capturing 40.8% of the total variance, with 10 cytokines contributing to the separation. Macrophage migration inhibitory factor (MIF) alone accounted for 92% of the total contribution. Further, receiver operating characteristics analysis revealed that MIF showed an acceptable ability to distinguish between patients and controls (area under the curve=0.79).Conclusions These results suggest that cytokines may play a role in LBP with MCs. The clinical significance of the findings is unknown. MIF strongly contributed to clustering of patients with LBP with MCs and controls, and might be a biomarker for MCs. Ultimately, these results may guide future research on novel treatments for this patient group.https://rmdopen.bmj.com/content/7/2/e001726.full |
| spellingShingle | Are Hugo Pripp Kjersti Storheim Lars Christian Haugli Bråten Monica Wigemyr Maria Dehli Vigeland John Anker Zwart Linda Margareth Pedersen Elisabeth Gjefsen Kristina Gervin Guro Goll Hans Christian D Aass Elina Schistad Kaja Kristine Selmer Macrophage migration inhibitory factor: a potential biomarker for chronic low back pain in patients with Modic changes RMD Open |
| title | Macrophage migration inhibitory factor: a potential biomarker for chronic low back pain in patients with Modic changes |
| title_full | Macrophage migration inhibitory factor: a potential biomarker for chronic low back pain in patients with Modic changes |
| title_fullStr | Macrophage migration inhibitory factor: a potential biomarker for chronic low back pain in patients with Modic changes |
| title_full_unstemmed | Macrophage migration inhibitory factor: a potential biomarker for chronic low back pain in patients with Modic changes |
| title_short | Macrophage migration inhibitory factor: a potential biomarker for chronic low back pain in patients with Modic changes |
| title_sort | macrophage migration inhibitory factor a potential biomarker for chronic low back pain in patients with modic changes |
| url | https://rmdopen.bmj.com/content/7/2/e001726.full |
| work_keys_str_mv | AT arehugopripp macrophagemigrationinhibitoryfactorapotentialbiomarkerforchroniclowbackpaininpatientswithmodicchanges AT kjerstistorheim macrophagemigrationinhibitoryfactorapotentialbiomarkerforchroniclowbackpaininpatientswithmodicchanges AT larschristianhauglibraten macrophagemigrationinhibitoryfactorapotentialbiomarkerforchroniclowbackpaininpatientswithmodicchanges AT monicawigemyr macrophagemigrationinhibitoryfactorapotentialbiomarkerforchroniclowbackpaininpatientswithmodicchanges AT mariadehlivigeland macrophagemigrationinhibitoryfactorapotentialbiomarkerforchroniclowbackpaininpatientswithmodicchanges AT johnankerzwart macrophagemigrationinhibitoryfactorapotentialbiomarkerforchroniclowbackpaininpatientswithmodicchanges AT lindamargarethpedersen macrophagemigrationinhibitoryfactorapotentialbiomarkerforchroniclowbackpaininpatientswithmodicchanges AT elisabethgjefsen macrophagemigrationinhibitoryfactorapotentialbiomarkerforchroniclowbackpaininpatientswithmodicchanges AT kristinagervin macrophagemigrationinhibitoryfactorapotentialbiomarkerforchroniclowbackpaininpatientswithmodicchanges AT gurogoll macrophagemigrationinhibitoryfactorapotentialbiomarkerforchroniclowbackpaininpatientswithmodicchanges AT hanschristiandaass macrophagemigrationinhibitoryfactorapotentialbiomarkerforchroniclowbackpaininpatientswithmodicchanges AT elinaschistad macrophagemigrationinhibitoryfactorapotentialbiomarkerforchroniclowbackpaininpatientswithmodicchanges AT kajakristineselmer macrophagemigrationinhibitoryfactorapotentialbiomarkerforchroniclowbackpaininpatientswithmodicchanges |